Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes

OBJECTIVE To assess prospectively the effect of benchmarking on quality of primary care for patients with type 2 diabetes by using three major modifiable cardiovascular risk factors as critical quality indicators. RESEARCH DESIGN AND METHODS Primary care physicians treating patients with type 2 diabetes in six European countries were randomized to give standard care (control group) or standard care with feedback benchmarked against other centers in each country (benchmarking group). In both groups, laboratory tests were performed every 4 months. The primary end point was the percentage of patients achieving preset targets of the critical quality indicators HbA1c, LDL cholesterol, and systolic blood pressure (SBP) after 12 months of follow-up. RESULTS Of 4,027 patients enrolled, 3,996 patients were evaluable and 3,487 completed 12 months of follow-up. Primary end point of HbA1c target was achieved in the benchmarking group by 58.9 vs. 62.1% in the control group (P = 0.398) after 12 months; 40.0 vs. 30.1% patients met the SBP target (P < 0.001); 54.3 vs. 49.7% met the LDL cholesterol target (P = 0.006). Percentages of patients meeting all three targets increased during the study in both groups, with a statistically significant increase observed in the benchmarking group. The percentage of patients achieving all three targets at month 12 was significantly larger in the benchmarking group than in the control group (12.5 vs. 8.1%; P < 0.001). CONCLUSIONS In this prospective, randomized, controlled study, benchmarking was shown to be an effective tool for increasing achievement of critical quality indicators and potentially reducing patient cardiovascular residual risk profile.

[1]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[2]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[3]  Eric R. Ziegel,et al.  Biostatistical Methods , 2002, Technometrics.

[4]  S. Iliffe,et al.  Bmc Medical Research Methodology Open Access the Hawthorne Effect: a Randomised, Controlled Trial , 2007 .

[5]  Li Yan,et al.  Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone. , 2011, Chinese medical journal.

[6]  J. Wens,et al.  Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP. , 2011, Primary care diabetes.

[7]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[8]  Sylvia J. Hysong,et al.  Meta-Analysis: Audit and Feedback Features Impact Effectiveness on Care Quality , 2009, Medical care.

[9]  J J Allison,et al.  Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. , 2001, JAMA.

[10]  A pragmatic cluster randomised controlled trial of a Diabetes REcall And Management system: the DREAM trial , 2007, Implementation science : IS.

[11]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[12]  S. Ebrahim Detection, adherence and control of hypertension for the prevention of stroke: a systematic review. , 1998, Health technology assessment.

[13]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[14]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[15]  B. Neal The Blood Pressure Lowering Treatment Trialists' Collaboration , 2001 .

[16]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[17]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[18]  Neil Chapman,et al.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[19]  C. Brotons,et al.  Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus , 2011, Cardiovascular diabetology.

[20]  M. Burnier,et al.  Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. , 2006, American journal of hypertension.

[21]  S. Kische,et al.  O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .

[22]  W. J. Elliott,et al.  Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review , 2008 .

[23]  F. J. Roethlisberger,et al.  Management and the Worker , 2003 .

[24]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[25]  A. Turchin,et al.  Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. , 2011, Archives of internal medicine.

[26]  Paul E. Johnson,et al.  Customized Feedback to Patients and Providers Failed to Improve Safety or Quality of Diabetes Care , 2009, Diabetes Care.

[27]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[28]  William Branch,et al.  Clinical Inertia , 2001, Annals of Internal Medicine.

[29]  David Machin,et al.  Sample Size Tables for Clinical Studies , 1997 .

[30]  S. Jacob,et al.  Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap? , 2010, Advances in therapy.

[31]  C. Brotons,et al.  Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries , 2013, European journal of preventive cardiology.

[32]  G. W. Snedecor Statistical Methods , 1964 .

[33]  R. Stolk,et al.  Clinical inertia in general practice: widespread and related to the outcome of diabetes care. , 2009, Family practice.

[34]  Residual vascular risk in T2DM: the next frontier , 2011 .

[35]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[36]  W. Gillanders,et al.  Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. , 2011, Archives of internal medicine.

[37]  F. J. Roethlisberger,et al.  Management and the Worker , 1941 .

[38]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[39]  M. Vandervoort,et al.  Barriers to Blood Pressure Control: A STITCH Substudy , 2011, The Journal of Clinical Hypertension.

[40]  Jane M. Young,et al.  Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback , 2006, Quality and Safety in Health Care.

[41]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[42]  M. Godwin,et al.  Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's, Nfld. , 2010, Canadian family physician Medecin de famille canadien.